We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Eidogen-Sertanty and Specs Release Kinase-Targeted Compound Library
Product News

Eidogen-Sertanty and Specs Release Kinase-Targeted Compound Library

Eidogen-Sertanty and Specs Release Kinase-Targeted Compound Library
Product News

Eidogen-Sertanty and Specs Release Kinase-Targeted Compound Library


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Eidogen-Sertanty and Specs Release Kinase-Targeted Compound Library "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Eidogen-Sertanty, Inc. and Specs have announced the launch of a small molecule library focused toward inhibitors of several protein kinase families.

This Kinase-Targeted Library represents the culmination of a co-marketing and collaborative service agreement between Eidogen-Sertanty and Specs.

Eidogen applied the Kinase Knowledgebase™ and eScreen® components of its DirectDesign™ discovery platform to select a subset of molecules from Specs' diverse compound collection.

These selected molecules were predicted to have good bioavailability and activity against a series of therapeutically relevant kinases.

A subset of the Kinase-Targeted Library was experimentally validated through screening conducted at Memorial Sloan-Kettering Cancer Center against several of its in-house targets.

Eidogen claims that, through its in silico eScreen activity assessment and prioritization process, it was found that only a small percentage of compounds needed to be screened to observe a 5-fold increase in hit rate relative to the original primary screening data.

"The eScreen data was overwhelmingly surprising to us, especially with respect to the observed enrichment in potential kinase inhibitors, which would have been missed otherwise," commented Dr. Hakim Djaballah, Head of Screening at Memorial Sloan Kettering Cancer Center in New York.

Under the terms of the co-marketing agreement, Specs will distribute the Kinase-focused library to its worldwide customer base of pharmaceutical and biotechnology companies, with Eidogen-Sertanty receiving royalties.

Advertisement